<![CDATA[Genmab — Februar 2023]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/topic/399169/genmab-februar-2023RSS for NodeMon, 08 Jun 2026 02:28:11 GMTWed, 01 Feb 2023 04:17:26 GMT60<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 17:49:03 GMT]]>Ret spændende gentogen. Med desværre er begge stoffer trukket væk fra cancer området. Nu i RRMS som jeg husker.

]]>https://dev.proinvestor.com/forum/post/7661609https://dev.proinvestor.com/forum/post/7661609Tue, 28 Feb 2023 17:49:03 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 17:34:06 GMT]]>Og hvis ofa kunne få revanche i Cll, står verden da ikke længere.

]]>https://dev.proinvestor.com/forum/post/7661606https://dev.proinvestor.com/forum/post/7661606Tue, 28 Feb 2023 17:34:06 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 17:32:38 GMT]]>Tak gentogen. Hjernebetændelse rammer 250.000 hvert år alene i usa https://www.hopkinsmedicine.org/health/conditions-and-diseases/encephalitis

]]>https://dev.proinvestor.com/forum/post/7661607https://dev.proinvestor.com/forum/post/7661607Tue, 28 Feb 2023 17:32:38 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 17:29:28 GMT]]>https://www.linkedin.com/posts/claus-johansen-729292_genmab-newtakeovertarget-tivdak-activity-7036295466224898049-VRdi?utm_source=share&utm_medium=member_ios Takeover target ?

]]>https://dev.proinvestor.com/forum/post/7661602https://dev.proinvestor.com/forum/post/7661602Tue, 28 Feb 2023 17:29:28 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 17:05:45 GMT]]>or better yet, surely they
can be combined 😉

]]>https://dev.proinvestor.com/forum/post/7661610https://dev.proinvestor.com/forum/post/7661610Tue, 28 Feb 2023 17:05:45 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 17:05:12 GMT]]>@gentogen this was from December - https://www.frontiersin.org/articles/10.3389/fneur.2020.602102/full - Dara competing with Ofa, wouldn't that be fun

]]>https://dev.proinvestor.com/forum/post/7661605https://dev.proinvestor.com/forum/post/7661605Tue, 28 Feb 2023 17:05:12 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 16:46:02 GMT]]>Alem-Ofa is effective in untreated CLL with ORR 98%, CR 48% and 60% bone marrow uMRD

]]>https://dev.proinvestor.com/forum/post/7661604https://dev.proinvestor.com/forum/post/7661604Tue, 28 Feb 2023 16:46:02 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 16:45:32 GMT]]>https://www.sciencedirect.com/science/article/pii/S0145212622001710?casa_token=__agdgKtAvsAAAAA:2rIEDbu4vlcRU7Ojw1dnxkXn27fiTFhQBWptE8T-1C5cHnE8HVdEzdFjlevKa1fsS0jhifGIEw

]]>https://dev.proinvestor.com/forum/post/7661603https://dev.proinvestor.com/forum/post/7661603Tue, 28 Feb 2023 16:45:32 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 16:45:06 GMT]]>Our Alem-Ofa dual-targeted immunotherapy study showed that it is an early example of a chemotherapy-free treatment option with several advantages even in the modern treatment era. First the treatment is of a limited and short duration of no longer than 4.5 months. Second, it was able to achieve rapid onset, deep and durable response; most patients needed no additional therapy in the next five years.

]]>https://dev.proinvestor.com/forum/post/7661608https://dev.proinvestor.com/forum/post/7661608Tue, 28 Feb 2023 16:45:06 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 16:34:32 GMT]]>https://assets.researchsquare.com/files/rs-2565559/v1/44257c98-f5d5-4bf9-8fe2-f350845789d7.pdf?c=1676475873

]]>https://dev.proinvestor.com/forum/post/7661600https://dev.proinvestor.com/forum/post/7661600Tue, 28 Feb 2023 16:34:32 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 16:34:05 GMT]]>For the first time, we report a successful approach to the treatment of refractory anti-NMDAR encephalitis
using the fully human anti-CD20 monoclonal antibody ofatumumab, which serves as an important
reference for the treatment of autoimmune encephalitis. In our cases, satisfactory clinical outcomes were still observed in anti-NMDR encephalitis
while first-line therapy failed. Thus, the case report provides reference for new treatment options of
autoimmune encephalitis

]]>https://dev.proinvestor.com/forum/post/7661596https://dev.proinvestor.com/forum/post/7661596Tue, 28 Feb 2023 16:34:05 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 15:30:21 GMT]]>I started 01.01.2023, 🙂

]]>https://dev.proinvestor.com/forum/post/7661597https://dev.proinvestor.com/forum/post/7661597Tue, 28 Feb 2023 15:30:21 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 15:11:35 GMT]]>2021 started with 3 red months after which we nicely rallied from 1900 to 3100+ ; all green months. That lasted the whole summer though, so maybe we should start vacations early 😉

]]>https://dev.proinvestor.com/forum/post/7661598https://dev.proinvestor.com/forum/post/7661598Tue, 28 Feb 2023 15:11:35 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 15:07:39 GMT]]>3rd red month in a row. Since the lows of 2011 we only once had 4 negative months in a row, at the end of 2017

]]>https://dev.proinvestor.com/forum/post/7661594https://dev.proinvestor.com/forum/post/7661594Tue, 28 Feb 2023 15:07:39 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 13:31:39 GMT]]>Den tabte voldgift må JW tage sin del af æren for. Lad os få afgørelsen og se om vi er fortabte. Det burde få ham til at være lidt ydmyg, hvis den nuværende voldgift tabes.

]]>https://dev.proinvestor.com/forum/post/7661599https://dev.proinvestor.com/forum/post/7661599Tue, 28 Feb 2023 13:31:39 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 11:26:18 GMT]]>Ja ok der mener jeg så en CEO skal måles på de resultater der kommer i hus og ikke den som fejler af den ene eller anden grund. Kurs stigning på +18% i snit sinde 2015 er ok og slutter i over 3400kr i år er det 8 år i træk. Over and out

]]>https://dev.proinvestor.com/forum/post/7661591https://dev.proinvestor.com/forum/post/7661591Tue, 28 Feb 2023 11:26:18 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 11:24:46 GMT]]>Så tror jeg, at jeg har udtrykt mig til strækkeligt om lønninger og det forhold, at øget (US) lønniveau ikke er en nødvendig forudsætning for, at tiltrække dygtige medarbejdere og skabe store succes. Slut herfra, for i dag 🙂

]]>https://dev.proinvestor.com/forum/post/7661592https://dev.proinvestor.com/forum/post/7661592Tue, 28 Feb 2023 11:24:46 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 11:19:03 GMT]]>Voldsomt er måske "voldsomt" at bruge .... men det er hvert fald en flot løn, taget årets begivenheder in mente. Nuvel væksten er god, men voldgiften har potentialet kostet 12-13 % af +100-120 mia. kr. Mindes ikke Novo nogensinde har leveret samme streg i regningen

]]>https://dev.proinvestor.com/forum/post/7661593https://dev.proinvestor.com/forum/post/7661593Tue, 28 Feb 2023 11:19:03 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 11:16:46 GMT]]>ADC Therapeutics Reports Fourth Quarter and Full Year 2022 - Cami (camidanlumab tesirine)

Based on the positive pivotal Phase 2 data, the Company is actively seeking a partner to progress this program.

]]>https://dev.proinvestor.com/forum/post/7661595https://dev.proinvestor.com/forum/post/7661595Tue, 28 Feb 2023 11:16:46 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 11:16:21 GMT]]>Jan lægger på +40 mio. i 2022 og med en tabt voldgift i baggagen i årets l
, så syns jeg det er voldsomt.

]]>https://dev.proinvestor.com/forum/post/7661590https://dev.proinvestor.com/forum/post/7661590Tue, 28 Feb 2023 11:16:21 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 11:16:06 GMT]]>Det kan man jo sige om alle de solide indikationer de har i pipelinen. Alle ved jo at under 10% kommer gennem nåleøjet. Men lige her har Genmab jo god track rekort med at vælge vinderne og stoppe med taberne i tide.

]]>https://dev.proinvestor.com/forum/post/7661585https://dev.proinvestor.com/forum/post/7661585Tue, 28 Feb 2023 11:16:06 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 11:13:36 GMT]]>Jamen jeg siger ikke Jan skal have mere end 8 mia. Kender som sagt ikke hans hyre for 2022 men vil mene en hyre ca. 50% under Novos CEO er ok. Så hvis Novo ligger på ca. 9 nu bør Jan ligge på
ca.6.

]]>https://dev.proinvestor.com/forum/post/7661584https://dev.proinvestor.com/forum/post/7661584Tue, 28 Feb 2023 11:13:36 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 11:13:10 GMT]]>Vi har vel ikke glemt solide "nyheden" omkring 2018/19... den har snart fortabt sig tågen.

]]>https://dev.proinvestor.com/forum/post/7661586https://dev.proinvestor.com/forum/post/7661586Tue, 28 Feb 2023 11:13:10 GMT<![CDATA[Reply to Genmab — Februar 2023 on Tue, 28 Feb 2023 11:12:25 GMT]]>Driften påvirkes ikke af den igangværende sag, hvis det bliver det totale nederlag. Hvad kursen vil falde, vil afhænge af hvor meget markedet har indregnet og det kan godt være nul eller mere/mindre. Aktien kan også falde mere end markedet har indregnet, hvis køen ved udgangen bliver tilstrækkelig stor i et kort tidsrum.

]]>https://dev.proinvestor.com/forum/post/7661601https://dev.proinvestor.com/forum/post/7661601Tue, 28 Feb 2023 11:12:25 GMT